Groupe d'Etude en Oncologie du Quebec

Titre	A Phase III, Multicenter, Randomized Placebo-Controlled Study of Atezolizumab (MPDL3280A) (Anti-PD-L1 Antibody) in Combination With Nab Paclitaxel Compared With Placebo With Nab Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer
Protocole ID	WO29522
ClinicalTrials.gov ID	NCT02425891
Type(s) de cancer	Sein
Phase	Phase III
Type étude	Traitement
Médicament	Atezolizumab (MPDL3280A) avec Nab Paclitaxel
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL HOPITAL DU SAINT-SACREMENT 1050 Ch Ste-Foy, Québec, QC, G1S 4L8
Ville	Québec
Investigateur(trice) principal(e)	Dre Louise Provencher
Coordonnateur(trice)	Isabelle Ouellet 418-682-7511 poste 4553
Statut	Fermé
Critètes d'éligibilité	Female > or = 18 years of age Metastatic or locally advanced, histologically documented Triple-Negative Breast Cancer (TNBC) No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Measurable disease Adequate hematologic and end-organ function
Critètes d'exclusion	Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases Leptomeningeal disease Pregnancy or lactation History of autoimmune disease Prior allogeneic stem cell or solid organ transplantation Positive test for HIV Active hepatitis B or hepatitis C

Groupe d'étude en oncologie du Québec